Healthcare Mergers, Acquisitions & Ventures Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions & Ventures Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergies
Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
February 2nd, 2008
Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti- inflammatory drugs, announced the preliminary safety results from its Phase I safety and tolerability study of MRX-4 in 16 patients suffering from allergic rhinitis (AR). MRX-4 was nasally administered as a single dose once a week for four consecutive weeks. The first administration was given without a nasal allergen challenge (NAC) while the subsequent three were carried out in conjunction with a NAC. The protocol was double-blinded and placebo-controlled. During the trial, no adverse effects were observed with blood analysis and pharmacokinetic data further indicating...
Source: Healthcare Mergers, Acquisitions & Ventures Week (2008-02-02)
|
